Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 10/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 10/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140138 | 0.86 | SLC5A1 (0.42) | SLC5A1SLC5A2MBOAT4CETP | |
| SCHEMBL20140209 | 0.85 | SLC5A1 (0.45) | SLC5A1SLC5A2CETP | |
| SCHEMBL20141555 | 0.79 | HTR2A (0.44) | SLC5A1SLC5A2 | |
| SCHEMBL20139430 | 0.74 | EPHX2 (0.33) | EPHX2TRPV1CYP1A2CYP2C19 | |
| SCHEMBL20154869 | 0.74 | SLC5A2 (0.53) | SLC5A1SLC5A2 | |
| SCHEMBL20140030 | 0.73 | SLC5A2 (0.80) | SLC5A1SLC5A2 | |
| SCHEMBL16682942 | 0.72 | SNCA (0.47) | SLC5A1SLC5A2CETPCYP1A2MAPT | |
| SCHEMBL20140227 | 0.69 | SLC5A1 (0.53) | SLC5A1SLC5A2CETPMAPT | |
| SCHEMBL31285025 | 0.68 | HTR2A (0.47) | — | |
| SCHEMBL13073515 | 0.68 | MBOAT4 (0.44) | MBOAT4SIGMAR1CYP1A2MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | SLC5A1 2/4885SLC5A2 1/4885MBOAT4 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.